
    
      The drug being tested in this study is called brentuximab vedotin. This study will look at
      efficacy, safety and PK of brentuximab vedotin in Chinese participants with
      relapsed/refractory CD30+ HL or sALCL.

      The study will enroll approximately 30 patients. Participants will receive:

      â€¢ Brentuximab vedotin 1.8 mg/kg

      All participants will be administered IV infusion on Day 1 each 3-week cycle until the sooner
      of disease progression, unacceptable toxicity, or completion of 16 cycles.

      This multi-center trial will be conducted in China only. The overall time to participate in
      this study is 3.5 years. Participants will make multiple visits to the clinic, and will be
      followed for overall survival (OS) every 12 weeks until death, withdrawal of consent, 18
      months after end of treatment (EOT) or study closure, whichever occurs first.
    
  